Skip to main content

Health condition · Clinically reviewed

Diffuse large B-cell lymphoma, aggressive, but often curable with modern therapy.

The most common non-Hodgkin lymphoma in the UK. First-line R-CHOP or POLA-R-CHP cures most patients, and CAR-T plus bispecifics have transformed relapsed disease.

Jump to treatment
A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Why trust this guide

  • 01

    Clinically reviewed

    Written by our editorial team and reviewed by a registered UK clinician before publication.

  • 02

    Sourced from guidance

    Checked against BSH, ESMO, NICE and peer-reviewed haemato-oncology sources you can see at the end.

  • 03

    Current for 2026

    Reflects modern UK practice including POLA-R-CHP, CAR-T therapy and bispecific antibodies for relapsed disease.

Key facts

DLBCL at a glance.

The essentials in plain English, what it is, how common, the main subtypes and how it is treated in the UK today.

  • What it is

    An aggressive but potentially curable non-Hodgkin lymphoma arising from mature B-lymphocytes, typically forming rapidly enlarging nodal or extranodal masses.

  • How common

    The most common non-Hodgkin lymphoma, roughly 30 to 40 per cent of NHL, with UK incidence around 7 per 100,000 per year and a peak in the 60s and 70s.

  • Subtypes

    WHO 2022 recognises DLBCL NOS with GCB and ABC cell-of-origin patterns, plus distinct entities like primary mediastinal, primary CNS, cutaneous leg-type and double or triple-hit high-grade lymphomas.

  • Presentation

    A rapidly growing lymph-node mass, B symptoms (fever, night sweats, weight loss of 10 per cent or more) and extranodal disease in roughly 40 per cent, especially GI, Waldeyer’s ring, testis, CNS, skin and bone.

  • Foundation therapy

    R-CHOP for six cycles remains standard first-line care, curing around 60 to 70 per cent, with POLA-R-CHP now preferred for many patients with IPI 2 to 5 disease.

  • Relapse options

    Salvage chemotherapy with autologous stem-cell transplant, CD19 CAR-T cell therapy and bispecific antibodies have transformed outcomes in relapsed and refractory disease.

Why this guide matters

A cancer with genuine cure in view.

DLBCL is aggressive, but decades of research have turned it into one of the great success stories in oncology. The three points below shape everything else on this page.

  • Precise diagnosis matters

    Excisional biopsy, immunohistochemistry and FISH testing decide whether this is DLBCL NOS, primary mediastinal disease, primary CNS lymphoma or a double-hit lymphoma, and each is treated differently.

  • First-line therapy cures most

    Six cycles of R-CHOP or POLA-R-CHP cure roughly two-thirds of patients, with CNS prophylaxis added when the CNS-IPI risk is high.

  • Relapse is no longer the end

    CD19 CAR-T cell therapy and bispecific antibodies now offer durable remission for many patients who would previously have run out of options.

How the diagnosis is made

From first swollen node to a full treatment plan.

The steps a UK haematology team will normally follow, in order, so you know what to expect and why each investigation matters.

  1. 01

    Assessing

    History and examination

    A structured review of lymphadenopathy, B symptoms, extranodal features, performance status and risk factors including HIV, hepatitis, transplant history and autoimmune disease.

  2. 02

    Assessing

    Excisional lymph-node biopsy

    A whole node removed under local or general anaesthetic, sent to a specialist haematopathology service for morphology, immunohistochemistry and molecular studies.

  3. 03

    Assessing

    Immunohistochemistry panel

    CD20, CD19, CD5, CD10, BCL6, MUM1, BCL2, MYC, Ki-67, p53 and EBER to confirm B-cell origin and assign GCB or ABC cell-of-origin using the Hans algorithm.

  4. 04

    Confirming

    FISH for MYC, BCL2 and BCL6

    Molecular testing to identify double-hit or triple-hit high-grade B-cell lymphoma, which needs more intensive treatment than DLBCL NOS.

  5. 05

    Confirming

    Staging PET-CT and bloods

    Whole-body PET-CT is the gold standard staging test, with FBC, U&Es, LFTs, LDH, beta-2 microglobulin, urate, calcium and viral screens for HIV, HBV and HCV.

  6. 06

    Confirming

    CNS and marrow assessment

    CSF cytology in high CNS-IPI patients and bone-marrow biopsy where PET-CT is equivocal or where cytopenias suggest marrow involvement.

  7. 07

    Preparing

    Baseline cardiac and fertility

    ECG and echocardiogram before anthracycline chemotherapy, plus a fertility-preservation discussion for anyone of reproductive age and MDT review at a specialist lymphoma centre.

Typical timeline: from first biopsy to starting treatment in one to three weeks at a specialist centre.

Symptoms

What DLBCL actually looks like.

A rapidly growing lump, B symptoms and a mix of nodal and extranodal features. Some presentations are urgent, and the last card below flags those.

  • Rapidly growing lymphadenopathy

    A firm, painless, quickly enlarging node in the neck, axilla, groin or mediastinum, often noticed over weeks rather than months.

  • B symptoms

    Unexplained fevers, drenching night sweats and weight loss of 10 per cent or more of body weight over six months.

  • Extranodal disease

    Around 40 per cent present outside lymph nodes, most often stomach, bowel, Waldeyer’s ring, testis, skin or bone.

  • Mediastinal mass and SVC obstruction

    A large chest mass can cause facial swelling, distended neck veins, cough and breathlessness, a haemato-oncology emergency.

  • CNS and spinal-cord involvement

    Headache, cranial-nerve palsies, focal neurology or cord compression demand urgent imaging and specialist input.

  • Cytopenias and hyperviscosity

    Anaemia, low platelets or high paraprotein-driven viscosity may reflect marrow, spleen or bulk disease.

  • Metabolic disturbance

    Hypercalcaemia, raised LDH, high urate and tumour-lysis features can appear at diagnosis or on starting treatment.

  • Red flag - acute deterioration

    Sudden breathlessness, altered consciousness or new focal neurology needs same-day assessment through emergency or acute-oncology pathways.

Treatment

How DLBCL is treated in the UK.

R-CHOP or POLA-R-CHP for six cycles first, intensified regimens for high-grade double-hit disease, and CAR-T or bispecifics for relapsed and refractory lymphoma.

  • R-CHOP for six cycles

    Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone, the long-standing standard first-line regimen with roughly 60 to 70 per cent cure rates.

  • POLA-R-CHP

    Polatuzumab vedotin replacing vincristine, based on the POLARIX trial, now used for many IPI 2 to 5 patients with improved progression-free survival.

  • CNS prophylaxis

    High-dose intravenous methotrexate or intrathecal chemotherapy for patients at high CNS-IPI risk to reduce brain and spinal relapse.

  • Stage I to II abbreviated care

    Shorter R-CHOP with involved-site radiotherapy, or full R-CHOP, guided by bulk, extranodal sites and PET response.

  • DA-EPOCH-R

    Dose-adjusted infusional regimen used in double or triple-hit high-grade B-cell lymphoma and primary mediastinal DLBCL.

  • Salvage chemotherapy plus ASCT

    R-DHAP, R-ICE or R-GDP followed by autologous stem-cell transplant for fit patients with chemosensitive relapsed disease.

  • CD19 CAR-T cell therapy

    Axi-cel, tisa-cel and liso-cel are NHS-approved for third-line disease and increasingly at second-line based on ZUMA-7 and TRANSFORM trials.

  • Bispecific antibodies

    Epcoritamab and glofitamab (CD20 x CD3) are approved third-line options with durable responses, delivered as outpatient step-up dosing.

Supportive care

Alongside chemoimmunotherapy, patients receive G-CSF to reduce neutropenia, tumour-lysis prophylaxis with allopurinol or rasburicase, PJP and antifungal prophylaxis, VTE assessment, hepatitis B antiviral cover, IVIG for hypogammaglobulinaemia, updated vaccinations and fertility-preservation input where appropriate.

What this guide is based on

The sources behind every claim on this page.

UK and international haemato-oncology guidance, WHO classification and NICE technology appraisals current at the time of last review.

Key references

Guidelines and standards we relied on.

A quiet reminder

This guide is for information, not medical advice.

Your haematology team knows your histology, staging and comorbidities and can tell you which parts apply to you. If in doubt, always follow their guidance.

  • British Society for Haematology (BSH). Guidelines on the management of diffuse large B-cell lymphoma.

  • ESMO Clinical Practice Guidelines. Diffuse large B-cell lymphoma: diagnosis, treatment and follow-up.

  • NICE. Technology appraisals for polatuzumab vedotin, axi-cel, tisa-cel, liso-cel, epcoritamab and glofitamab in DLBCL.

  • WHO Classification of Haematolymphoid Tumours, 5th edition (2022).

Red flags

When DLBCL needs urgent attention.

Any of these deserves same-day contact with the haemato-oncology team or the acute-oncology helpline your unit provides.

  • Superior vena cava obstruction

    Facial and neck swelling, distended chest veins and breathlessness from a mediastinal mass need same-day imaging and haemato-oncology review.

  • Spinal-cord compression

    New back pain with leg weakness, sensory change or bladder disturbance is an emergency needing urgent MRI and steroids.

  • CNS involvement

    Headache, cranial-nerve palsies, confusion or focal weakness requires urgent MRI brain and CSF analysis.

  • Tumour lysis syndrome

    High tumour burden, raised urate, LDH, potassium or phosphate on starting treatment risks acute kidney injury and arrhythmia.

  • Neutropenic sepsis

    Fever of 38 degrees or more within the neutropenic window after chemotherapy is a medical emergency needing IV antibiotics within an hour.

  • Hepatitis B reactivation

    Rituximab and steroids can reactivate occult hepatitis B, so screening and antiviral prophylaxis are essential.

  • Cytokine release with CAR-T

    Fever, hypotension or hypoxia after CAR-T needs immediate specialist assessment for tocilizumab and supportive care.

  • ICANS neurotoxicity

    Confusion, tremor, dysphasia or seizures after CAR-T or bispecifics needs urgent neuro-oncology input and steroids.

  • Testicular or breast disease

    These sites carry high CNS-relapse risk and always warrant CNS-directed prophylaxis alongside systemic therapy.

Living with it

An intense treatment, and a life beyond it.

Four things that make the biggest difference throughout the journey, from the first cycle of chemotherapy to survivorship years later.

A quiet reminder

You are not walking this alone.

Specialist nurses, Blood Cancer UK, Lymphoma Action and Macmillan can support you and your family throughout diagnosis, treatment and follow-up.

  1. 01 Treatment

    Cure is the aim

    DLBCL is aggressive but potentially curable, and modern first-line therapy sends most patients into long-term remission after six cycles.

  2. 02 Support

    Lean on the team

    Specialist nurses, Blood Cancer UK, Lymphoma Action and Macmillan can help with symptoms, finance, fatigue and family support throughout treatment.

  3. 03 Recovery

    Survivorship matters

    Long-term follow-up covers cardiac health, secondary cancers, endocrine change and fatigue, with tailored screening for each risk.

  4. 04 Vigilance

    Know the relapse signs

    New lumps, returning B symptoms or unexplained weight loss during follow-up should trigger an early call to the lymphoma team.

Frequently asked

Everything we get asked about DLBCL.

Quick answers on cure rates, subtypes, first-line therapy, CAR-T and bispecific antibodies.

  • What is diffuse large B-cell lymphoma?

    Diffuse large B-cell lymphoma, or DLBCL, is an aggressive but potentially curable cancer of mature B-lymphocytes. It is the most common non-Hodgkin lymphoma in the UK, accounting for around 30 to 40 per cent of cases, and usually presents with rapidly enlarging lymph nodes or extranodal masses.

  • Can DLBCL be cured?

    Yes. Around 60 to 70 per cent of patients are cured with first-line R-CHOP or POLA-R-CHP chemoimmunotherapy for six cycles. For those who relapse or fail first-line treatment, options like salvage chemotherapy with autologous stem-cell transplant, CD19 CAR-T cell therapy and bispecific antibodies now offer durable remission and cure for many.

  • What is the difference between GCB and ABC subtypes?

    DLBCL is classified by cell of origin into germinal-centre B-cell (GCB) and activated B-cell (ABC) subtypes using the Hans algorithm on immunohistochemistry. GCB tumours generally carry a better prognosis, while ABC tumours are more aggressive. Molecular tools like LymphGen are refining this further and guiding trial selection.

  • What is a double-hit lymphoma?

    A double-hit or triple-hit high-grade B-cell lymphoma carries MYC rearrangement plus BCL2 and/or BCL6 rearrangements on FISH testing. These aggressive tumours behave more aggressively than DLBCL NOS and are usually treated with intensified regimens like DA-EPOCH-R rather than standard R-CHOP.

  • What is CAR-T cell therapy?

    CAR-T uses your own T-cells, re-engineered to target the CD19 protein on lymphoma cells. Three products (axi-cel, tisa-cel and liso-cel) are NHS-approved for relapsed or refractory DLBCL and, based on the ZUMA-7 and TRANSFORM trials, are increasingly used at second-line for chemotherapy-resistant disease.

  • What are bispecific antibodies?

    Bispecific antibodies like epcoritamab and glofitamab bind CD20 on lymphoma cells and CD3 on T-cells, bringing them together to trigger tumour killing. Both are NHS-approved for third-line DLBCL and offer meaningful, sometimes durable responses, delivered as outpatient step-up dosing with careful monitoring for cytokine release.

Related content

Keep reading.

Pulse Healthcare concierge

Send us your enquiry

A concierge service for UK private healthcare. We match you with the best vetted clinics and consultants in our network - they then contact you directly.

So we can match you to the right clinician close to you.

We reply to every enquiry within 24 hours (Mon–Fri). Confidential - your details are never shared outside our vetted consultant network.